Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 2001, p. 2598-2603, Vol. 45, No. 9
Service de Bactériologie-Virologie,
Hôpital de Bicêtre, Assistance Publique/Hôpitaux de
Paris, Faculté de Médecine Paris-Sud, 94275 Le
Kremlin-Bicêtre,1 and Laboratoire
de Bactériologie, Faculté de Médecine,
Université d'Auvergne, 63001 Clermont-Ferrand,3 France, and
Department of Medical Microbiology, Faculty of Medicine,
University of Pretoria, 0001 Pretoria, South Africa2
Received 8 December 2000/Returned for modification 28 March
2001/Accepted 22 June 2001
Pseudomonas aeruginosa GW-1 was isolated in 2000 in
South Africa from blood cultures of a 38-year-old female who developed nosocomial pneumonia. This isolate harbored a self-transferable ca.
100-kb plasmid that conferred an expanded-spectrum cephalosporin resistance profile associated with an intermediate susceptibility to
imipenem. A Clavulanic acid-inhibited extended-spectrum
We have recently identified another Ambler class A Mobile cassettes contain genes most often mediating antibiotic
resistance and a cassette recombination site, designated the 59-base
element (59-be) (9, 10). The 59-be sites vary in length (57 to 141 bp) and structure, but they are all bounded by a core
site (GTTRRRY) at the recombinant crossover point and an
inverse core site (RYYYAAC) at the 3' end of the inserted
gene (4, 9). Integrons are genetic elements capable of
integrating individual gene cassettes by a site-specific
recombination mechanism that involves a DNA integrase, IntI; an
integron-specific recombination site, attI; and 59-be
(4, 9, 10). The 5' conserved segment (5'-CS) of the
integrons contains the integrase gene (intI) and the
recombination site attI1. The 3'-CS of class 1 integrons
carries the antisepsis resistance
qacE While analyzing carbapenem-resistant P. aeruginosa isolates
from South Africa, we retained a P. aeruginosa isolate that
was resistant to ceftazidime with an unusual substrate profile that included imipenem, according to preliminary analysis. Thus, the Bacterial strains.
P. aeruginosa clinical isolate
GW-1 was identified with the API-20 NE system (bioMérieux, Marcy
l'Etoile, France). E. coli DH10B was the host for cloning
experiments, and in vitro-obtained rifampin-resistant P. aeruginosa PU21 was used as a recipient strain for conjugative
transfer (30).
Susceptibility testing.
Antibiotic-containing disks were
used for routine antibiograms by the disk diffusion assay
(Sanofi-Diagnostic Pasteur, Marnes-la-Coquette, France) as previously
described (27). The double-disk synergy test was performed
with disks containing ceftazidime and amoxicillin-clavulanic acid on
Mueller-Hinton agar plates, and the results were interpreted as
described previously (11). MICs were determined by an agar dilution technique with Mueller-Hinton agar (Sanofi-Diagnostic Pasteur)
with an inoculum of 104 CFU, as described previously
(27). All plates were incubated at 37°C for 18 h at
ambient atmosphere. MICs of PCR and hybridization experiments.
Whole-cell DNA of
P. aeruginosa GW-1 was extracted as described previously
(27). This DNA was used as a template in standard PCR
conditions (36) with a series of primers designed for the detection of class A Cloning experiments, recombinant plasmid analysis, and DNA
sequencing.
The obtained PCR fragment (1.8 kb) with 5'-CS and
3'-CS integron primers was purified with a QIAquick column (Qiagen,
Courtaboeuf, France) and cloned into the SrfI site of
plasmid pPCR Cam SK(+) (Stratagene, Amsterdam, The Netherlands).
Recombinant plasmids were selected onto Trypticase soy (TS) agar plates
containing amoxicillin (100 µg/ml) and chloramphenicol (30 µg/ml).
The cloned DNA fragment inserted into one of the recombinant plasmids
(pLAP-1) was sequenced on both strands with an Applied Biosystems
sequencer (ABI 377). The nucleotide and deduced amino acid sequences
were analyzed and compared to sequences available over the Internet at
the National Center for Biotechnology Information website
(http://www.ncbi.nlm.nih.gov).
Plasmid study.
Conjugation experiments were performed with
P. aeruginosa GW-1 and in vitro-obtained rifampin-resistant
P. aeruginosa strain PU21 in solid and liquid media at
37°C (27). Transconjugants were selected on TS agar
plates containing 150 µg of rifampin per ml and 5 µg of ceftazidime
per ml. Plasmid DNAs of P. aeruginosa GW-1 and
transconjugant P. aeruginosa PU21 were extracted with the
Qiagen plasmid DNA maxi kit and analyzed by electrophoresis with a
0.8% agarose gel (Gibco BRL-Life Technologies, Cergy-Pontoise, France), as previously described (36). Plasmid DNAs
extracted from E. coli NCTC 50192 were used as size
standards (6).
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.9.2598-2603.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
GES-2, a Class A
-Lactamase from
Pseudomonas aeruginosa with Increased Hydrolysis of
Imipenem
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactamase gene, blaGES-2, was
cloned from whole-cell DNA of P. aeruginosa GW-1 and
expressed in Escherichia coli. GES-2, with a pI value of
5.8, hydrolyzed expanded-spectrum cephalosporins, and its substrate
profile was extended to include imipenem compared to that of GES-1,
identified previously in Klebsiella pneumoniae. GES-2
activity was less inhibited by clavulanic acid, tazobactam and imipenem
than GES-1. The GES-2 amino acid sequence differs from that of GES-1 by
a glycine-to-asparagine substitution in position 170 located in the
omega loop of Ambler class A enzymes. This amino acid change may
explain the extension of the substrate profile of the plasmid-encoded
-lactamase GES-2.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactamases (ESBLs) conferring resistance to expanded-spectrum
cephalosporins have been reported, first in
Enterobacteriaceae and then in Pseudomonas aeruginosa (11, 23). Rare reports of TEM- and
SHV-type ESBLs in P. aeruginosa are known (SHV-2a, TEM-4,
TEM-24, and TEM-42 [15, 23, 31]), while they have been
extensively described in Enterobacteriaceae
(11). Three non-TEM-, non-SHV-type ESBLs have been
reported in P. aeruginosa, i.e., PER-1, VEB-1, and OXA-18
-lactamases (20, 25, 27, 38). The PER-1
-lactamase gene is widespread in Turkey, although not reported as
plasmid mediated in P. aeruginosa (39). VEB-1
-lactamase, originally described in Escherichia coli and
Klebsiella pneumoniae isolates in Vietnam, has been found in
P. aeruginosa and enterobacterial isolates in Thailand
(8, 29, 38).
-lactamase,
GES-1, in a K. pneumoniae isolate in French Guiana
(28). It was found to be remotely related to other ESBLs.
This ESBL differs by two amino acid substitutions from IBC-1
-lactamase recently found in an Enterobacter cloacae
isolate in Greece (7). blaVEB-1,
blaGES-1, and blaIBC-1
are plasmid located and are part of gene cassettes integrated into
class 1 integrons (7, 28, 29).
1 gene; the sul1 gene, which
confers resistance to sulfonamides; and an open reading frame (ORF) of unknown function, ORF5 (26).
-lactamase content of this strain was further characterized. A
plasmid-mediated Ambler class A ESBL was identified with a substrate profile extended to imipenem but with hydrolysis rates lower than those
of the chromosome-encoded carbapenem-hydrolyzing class A
-lactamases
NmcA, SME-1/2, and IMI-1 identified in rare isolates of
E. cloacae and Serratia marcescens (19, 21,
24, 33, 35) and of the recently reported plasmid-encoded
-lactamase KPC-1 from K. pneumoniae (40).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-lactams were determined alone or in
combination with a fixed concentration of clavulanic acid (2 µg/ml)
and tazobactam (4 µg/ml). MIC results were interpreted according to
the guidelines of the National Committee for Clinical Laboratory
Standards (22).
-lactamase genes and their extended-spectrum derivatives found in enterobacterial and P. aeruginosa
isolates: blaTEM, blaSHV,
blaPER-1/
2, blaVEB-1,
blaToho-1/
2, blaSFO-1,
blaGES-1, and blaCTX-M-2
(8, 28). Similarly, a series of primers were designed for
detection of genes coding for acquired carbapenem-hydrolyzing
-lactamases such as Van3 (5'-CCTGAGGGGATGACTAAA-3') and
Van6 (5'-GTTATGCACTAC GAAGGC-3') for
blaSME-1 (21); I4
(5'-CTAATGAAATAG GAGTAC-3') and I5
(5'-AACAGATTTCAATGGCAGG-3') for
blaNMC-A (19), VIM-B and VIMF for
blaVIM-1/VIM-2 (30) and Imp-1
(5'-CTACCGCAGCAGAGTCTTTGC-3') and Imp-2
(5'-GAACAACCAGTTTTGCCTTAC C-3') for
blaIMP-1 (2). Since several
-lactamase genes are part of gene cassettes that are class 1 integron encoded, primers located in the 5'-CS (INT2F,
5'-TCTCGGGTAACATCAAGG-3') and 3'-CS (5'-AAGCAGACTTGACCTGA-3') regions were used for PCR
amplifications (14). Southern hybridizations were
performed as described by Sambrook et al. (36) using the
ECL nonradioactive labeling and detection kit (Amersham Pharmacia
Biotech, Orsay, France). Natural plasmid pGW-1 was hybridized with a
PCR-generated probe consisting of the internal 860-bp PCR fragment for
blaGES-1, as described previously
(28).
-Lactamase purification and isoelectric focusing (IEF)
analysis.
Cultures of E. coli DH10B(pLAP-1) were grown
overnight at 37°C in 4 liters of TS broth containing amoxicillin (100 µg/ml).
-Lactamase was purified with exactly the same protocol as
that described for GES-1 (28). Briefly, the
-lactamase
extract was sonicated, cleared by ultracentrifugation, loaded on a
Q-Sepharose column, and eluted with a linear NaCl gradient. The purity
of the enzyme was estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis (36).
-lactamase from a culture of E. coli DH10B(pLAP-1) and
nonpurified extracts of 100-ml cultures of P. aeruginosa
GW-1 and one of its P. aeruginosa PU21 transconjugants were
submitted to IEF analysis. The focused
-lactamases were detected by
overlaying the gel with 1 mM nitrocefin (Oxoid, Dardilly, France) in
100 mM phosphate buffer (pH 7.0). The pI values were determined and
compared to those of known
-lactamases, including GES-1
-lactamase.
Kinetic measurements.
Purified
-lactamase was used for
kinetic measurements performed at 30°C with 100 mM sodium phosphate
(pH 7.0) with an ULTROSPEC 2000 UV spectrophotometer (Amersham
Pharmacia Biotech) as previously described for the biochemical analysis
of GES-1
-lactamase (28).
-lactamase from E. coli DH10B(pLAP-1) was obtained as described previously
(29). One unit of enzyme activity was defined as the
activity which hydrolyzed 1 µmol of benzylpenicillin per min per mg
of protein. The total protein content was measured with the DC Protein
assay kit (Bio-Rad, Ivry-sur-Seine, France). Specific activity was also determined with 100 µM ceftazidime as a substrate.
Nucleotide sequence accession number. The nucleotide sequence data reported in this paper will appear in the GenBank nucleotide database under accession no. AF326355.
| |
RESULTS |
|---|
|
|
|---|
Properties of P. aeruginosa isolate GW-1. GW-1 was isolated in May 2000 at the Pretoria Academic Hospital, Pretoria, Republic of South Africa, from a 38-year-old Zimbabwean refugee hospitalized for cerebral malaria. On the 12th day of her hospitalization in the intensive care unit, she developed nosocomial pneumonia, and blood cultures grew P. aeruginosa GW-1. Empirical treatment with a combination of imipenem and amikacin was unsuccessful. Imipenem was replaced after 3 days with aztreonam, and her clinical condition improved remarkably. She received no treatment prior to her hospitalization in South Africa.
P. aeruginosa GW-1 exhibited a broad spectrum of resistance to expanded-spectrum cephalosporins and an intermediate susceptibility to imipenem, according to antibiotic susceptibility testing by disk diffusion. Double-disk synergy testing remained negative with clavulanate- and ceftazidime-containing disks. P. aeruginosa GW-1 was also resistant to kanamycin, gentamicin, netilmicin, fluoroquinolones, sulfonamides, and tetracycline and susceptible to tobramycin. Preliminary experiments with crude extracts of a culture of P. aeruginosa GW-1 showed that imipenem hydrolysis was detectable (data not shown).Cloning and sequencing of the
-lactamase gene.
Preliminary
PCR detection of most of the class A ESBLs and
carbapenem-hydrolyzing
-lactamase genes failed (data not shown). However, PCR amplification was positive with primers for
blaGES-1. With whole-cell DNA of P. aeruginosa GW-1 as a template and consensus primers for 5'-CS and
3'-CS ends of class 1 integrons, a 1.8-kb DNA fragment was obtained. It
was cloned into the SrfI site of plasmid pPCR Cam SK(+),
yielding recombinant plasmid pLAP-1. Sequence analysis of the cloned
fragment revealed an 864-bp-long ORF encoding a 287-amino-acid
preprotein. This protein was a
-lactamase with the STFK tetrad and
structural elements characteristic of the active site of an Ambler
class A
-lactamase (Fig. 1) (12). The
-lactamase, designated GES-2, had one amino acid change (glycine to
asparagine in position 170) and three amino acid changes compared to
GES-1 and IBC-1, respectively (Fig. 1). The G+C content of blaGES-2 was 51.5%, a value which is not within
the range of G+C content of P. aeruginosa genes (60.1 to
69.5%).
|
-lactamases (7, 28). The highest percentage of amino
acid identity was 36%, found with either carbenicillinase GN79 from
Proteus mirabilis, a constitutive penicillinase from Yersinia enterocolitica YENT, or the L-2 chromosomally
encoded extended-spectrum
-lactamase from Stenotrophomonas
maltophilia.
Transfer of
-lactam resistance.
Transconjugant P. aeruginosa PU21 strains were obtained with P. aeruginosa GW-1 as a donor. They showed a broad-spectrum
-lactam resistance phenotype, including an increased resistance
against imipenem (Table 1). A slightly positive
double-disk synergy test was done, with transconjugants indicating the
presence of an ESBL (data not shown). Cotransferred antibiotic
resistance markers were those carrying resistance for kanamycin,
gentamicin, netilmicin, and sulfonamides. The analysis of plasmid
content of P. aeruginosa GW-1 and its transconjugant
revealed a ca. 100-kb plasmid, designated pGW-1 (data not shown).
Hybridization using an internal probe for
blaGES-1 confirmed the presence of a
blaGES-1-like gene on plasmid pGW-1 found in
P. aeruginosa GW-1 and its transconjugant (data not shown).
|
-Lactam susceptibility.
MICs of
-lactams for P. aeruginosa GW-1 mirrored those for its transconjugant (Table 1).
The GES-2-producing P. aeruginosa strains were characterized
by resistance to carbenicillin, ureidopenicillins, cefotaxime, and
ceftazidime and by an intermediate susceptibility to aztreonam (Table
1). The MIC of imipenem was eightfold higher for P. aeruginosa PU21(pGW-1) than that for P. aeruginosa PU21 (Table 1). A similar trend of resistance was noted once
blaGES-2 was expressed in E. coli
DH10B. However, in this latter case, the recombinant strain was of
intermediate susceptibility to extended-spectrum cephalosporins and
susceptible to imipenem (Table 1). GES-2-producing E. coli DH10B(pLAP-1) was less resistant to cephalosporins
than GES-1-producing E. coli DH10B(pC1) (Table 1). The
imipenem MIC for E. coli DH10B(pLAP-1) was only slightly
higher than that for E. coli DH10B (Table 1).
-lactam activities
against the GES-2-producing E. coli strain as previously found for the GES-1-producing E. coli strain (Table 1).
Clavulanate did not lower significantly the
-lactam MICs for the
GES-2-producing P. aeruginosa strains (Table 1). This result
was likely due to a concomitant induction of the chromosomal
cephalosporinase of P. aeruginosa.
IEF analysis and kinetic parameters.
IEF analysis showed that
P. aeruginosa GW-1, its transconjugant, and E. coli DH10B(pLAP-1) had
-lactamase activities with a pI value of
5.8, corresponding to that of GES-2 and identical to that of GES-1
(data not shown).
-Lactamase activities with a pI value of 8 to 8.5 were also detected for P. aeruginosa GW-1 and its
transconjugant corresponding to the chromosomal
cephalosporinase of P. aeruginosa. A nonidentified
-lactamase with a pI of 7.5 was found in GW-1 and in its
transconjugant. Additional PCR experiments with whole-cell DNAs of
P. aeruginosa GW-1 and its transconjugants as templates and
primers for the detection of OXA-1, OXA-2, OXA-3, OXA-10, OXA-18, and
OXA-20 genes failed (data not shown).
-lactamase GES-2 was 720 mU · mg of protein
1, determined with 100 µM
benzylpenicillin as a substrate. Its overall recovery was 70% with a
20-fold purification. The purity of the enzyme was estimated to be 90%
according to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
analysis. Kinetic parameters of GES-2 showed its broad-spectrum
activity against most
-lactams, except aztreonam and meropenem
(Table 2). The hydrolysis rates of GES-2 for penicillins
were similar to those of GES-1 because the Km
values were 10-fold lower. However, the hydrolysis efficiency of GES-2
for extended-spectrum cephalosporins was slightly lower than that of
GES-1
-lactamase. Although ceftazidime was hydrolyzed, its kinetic
parameters could not be determined precisely. This was due to a very
high Km value (>3,000 µM), reflecting a very low affinity of GES-2 for ceftazidime. Nevertheless, its
Vmax value was high (data not shown), and the
specific activity of GES-2 was 57 mU · mg
1 with
100 µM ceftazidime as a substrate. As reported for GES-1 (28), high
kcat/Km values were
obtained for most cephalosporins for GES-2 when expressed in millimolar
units and not, as usual for an ESBL activity of a class A
enzyme, in micromolar units.
|
|
Genetic environment of blaGES-2.
Upstream of blaGES-2, two putative promoter
sequences named P1 and P2 were located in the
structural integrase gene (data not shown). Comparison of
P1 with known promoters for which expression studies were
performed (5, 13) identified P1 as a weak
promoter. As described, the insertion of three guanosine molecules 119 bases downstream of the promoter P1 creates a secondary
promoter (P2) for blaGES-1
expression. This triple nucleotide insertion brings the spacing between
the
35 and
10 regions of P2 to 17 bp. Therefore, P2 expression may be responsible for 90% of
blaGES-2 transcription, as shown for other genes
(5, 13). The blaGES-2 gene cassette which was inserted at the attI recombination site has a core
site (GTTAGAC) and an inverse core site (GTCTAAC).
Downstream of this gene, the 59-be sequence was made up of 110 bp. It was exactly identical to that found downstream of
blaIBC-1 and shared 70% nucleotide identity
within the 19-bp-long and truncated 59-be of
blaGES-1 (data not shown).
| |
DISCUSSION |
|---|
|
|
|---|
This report characterized another non-SHV-, non-TEM-type ESBL,
showing that class A ESBLs are not limited to SHV and TEM derivatives. GES-2
-lactamase is the fourth example of a non-TEM-, non-SHV-type ESBL in P. aeruginosa after PER-1, VEB-1, and OXA-18. A
study of the GES-2-producing P. aeruginosa GW-1 isolate
further indicated that ESBL genes in P. aeruginosa are
difficult to detect by double-disk synergy tests (23) and
may therefore be clinically underestimated.
GES-2
-lactamase is also the third example of a GES-type ESBL, in
addition to GES-1 from K. pneumoniae ORI-1 (28)
and IBC-1 from E. cloacae HT9 (7). The natural
producer of the GES-type enzymes remains to be determined. Indeed,
isolation of a GES-2 gene in P. aeruginosa with a G+C
content of non-P. aeruginosa origin indicated a horizontal
transfer of blaGES genes in gram-negative species.
One interesting aspect of this study is the comparison of the substrate
profiles of GES-1 and GES-2. A glycine-to-asparagine substitution in
GES-2 extended its activity to imipenem. This substitution occurred in
an amino acid position of the omega loop of class A
-lactamases that
is of primary importance in the catalytic activity of these enzymes
(3, 16). This substitution may enlarge the pocket that
houses the hydroxyethyl moiety of imipenem on the alpha face of the
acyl enzyme for GES-2 (17, 18).
GES-2, like GES-1 and IBC-1
-lactamases and also like the class A
enzymes with significant catalytic efficiency against imipenem (i.e.,
the chromosomally encoded
-lactamases SME-1/2, IMI-1, and Nmc-A and
the plamid-encoded KPC-1 enzyme [40]), contains two
cysteine residues in positions 69 and 238 that may form a disulfide
bridge. The catalytic activity
(kcal/Km, expressed in millimoles per second) of GES-2 versus that of imipenems (9 and 520, respectively) remained much lower than those of the
carbapenem-hydrolyzing
-lactamases such as SME-1 (33).
Thus, as reported (34), this cysteine bridge may enable
the catalytic site to bind imipenem, but other amino acid residues are
likely to be involved in the significant catalytic efficiency of the
carbapenem-hydrolyzing enzymes against imipenem.
The IC50 of imipenem for GES-2 was similar to the values of
other class A
-lactamases like TEM-1 (Table 3). Inhibitory activity profiles of GES-1, IBC-1, and GES-2 showed that clavulanic acid and
tazobactam are similarly active against GES-2 and IBC-1 but less so
against GES-1.
Comparison of the surrounding sequences of blaGES-2 to those of blaGES-1 and blaIBC-1 showed that blaGES genes are part of gene cassettes. Identification of an identical 59-be consisting of 110 bp for blaGES-2 and blaIBC-1 indicated the spread of an identical gene cassette among P. aeruginosa and enterobacterial isolates. Additionally, it may confirm the hypothesis that a deletion occurs in the 59-be of the blaGES-1 cassette (28).
A striking similarity may be drawn between VEB and GES
-lactamase
genes. They encode class A ESBLs, are located on broad-host-range conjugative plasmids, are part of gene cassettes in class 1 integrons, and are found in gram-negative isolates, and their origin (natural producer) remains unknown. Additionally, they may have spread worldwide, since VEB
-lactamases have been isolated in southeastern Asia and recently in Kuwait (8, 20, 29, 32, 38); GES
-lactamases are found in French Guiana, Greece, and now South Africa
(7, 28).
This work shows that plasmid- and integron-mediated genes encoding
ESBLs with some carbapenem hydrolytic activity are not limited to the
Ambler class B
-lactamase genes. GES-2
-lactamase may contribute
in part to the decreased susceptibility of P. aeruginosa to
imipenem. However, once expressed from a multicopy vector in E. coli, blaGES-2 expression did not
significantly increase the imipenem MIC, thus making its clinical
detection in enterobacterial isolates by a simple susceptibility study unlikely.
Finally, this report indicates that a class A
-lactamase with a
substrate profile extended to imipenem may be selected in vivo through
a single amino acid substitution in an ESBL sequence.
| |
ACKNOWLEDGMENTS |
|---|
This work was financed by a grant from the Ministère de l'Education Nationale et de la Recherche (grant UPRES, JE-2227), Université Paris XI, Paris, France.
We thank M. J. Pitout, A. M. S. Van Straten, and A. Laubscher for their contributions.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Service de Bactériologie-Virologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre Cedex, France. Phone: 33-1-45-21-36-32. Fax: 33-1-45-21-63-40. E-mail: nordmann.patrice{at}bct.ap-hop-paris.fr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ambler, R. P.,
A. F. Coulson,
J.-M. Frère,
J. M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Lévesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-270.
|
| 2. |
Arakawa, Y.,
M. Murakami,
K. Suzuki,
H. Ito,
R. Wacharotayankun,
S. Ohsuka,
N. Kato, and M. Otha.
1995.
A novel integron-like element carrying the metallo- -lactamase gene blaIMP.
Antimicrob. Agents Chemother.
39:1612-1615[Abstract].
|
| 3. |
Banerjee, S.,
U. Pieper,
G. Kapadia,
L. K. Pannell, and O. Herzberg.
1998.
Role of the omega-loop in the activity, substrate specificity, and structure of class A -lactamase.
Biochemistry
37:3286-3296[CrossRef][Medline].
|
| 4. |
Collis, C. M., and R. M. Hall.
1992.
Site-specific deletion and rearrangement of integron insert genes catalyzed by the integron DNA integrase.
J. Bacteriol.
174:1574-1585 |
| 5. | Collis, C. M., and R. M. Hall. 1995. Expression of antibiotic resistance genes in the integrated cassettes of integrons. Antimicrob. Agents Chemother. 39:155-162[Abstract]. |
| 6. |
Danel, F.,
L. M. C. Hall,
D. Gür, and D. Livermore.
1995.
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
39:1881-1884[Abstract].
|
| 7. |
Giakkoupi, P.,
L. S. Tzouvelekis,
A. Tsakris,
V. Loukova,
D. Sofianou, and E. Tzelepi.
2000.
IBC-1, a novel integron-associated class A -lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain.
Antimicrob. Agents Chemother.
44:2247-2253 |
| 8. |
Girlich, D.,
L. Poirel,
A. Leelaporn,
A. Karim,
C. Tribuddharat,
M. Fennewald, and P. Nordmann.
2001.
Molecular epidemiology of the integron-located VEB-1 extended-spectrum -lactamase in nosocomial enterobacterial isolates in Bangkok, Thailand.
J. Clin. Microbiol.
39:175-182 |
| 9. | Hall, R. M., D. E. Brookes, and H. W. Stokes. 1991. Site-specific insertion of genes into integrons: role of the 59-base element and determination of the recombination cross-over point. Mol. Microbiol. 5:1941-1959[Medline]. |
| 10. | Hall, R. M., and C. M. Collis. 1995. Mobile gene cassettes and integrons: capture and spread of genes by site-specific recombination. Mol. Microbiol. 15:593-600[CrossRef][Medline]. |
| 11. |
Jarlier, V.,
M.-H. Nicolas,
G. Fournier, and A. Philippon.
1988.
Extended broad-spectrum -lactamases conferring transferable resistance to newer -lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.
Rev. Infect. Dis.
10:867-878[Medline].
|
| 12. |
Joris, B.,
P. Ledent,
O. Dideberg,
E. Fonze,
J. Lamotte-Brasseur,
J. A. Kelly,
J. M. Ghuysen, and J.-M. Frère.
1991.
Comparison of the sequences of class A -lactamases and of the secondary structure elements of penicillin-recognizing proteins.
Antimicrob. Agents Chemother.
35:2294-2301 |
| 13. | Lévesque, C., S. Brassard, J. Lapointe, and P. H. Roy. 1994. Diversity and relative strength of tandem promoters for the antibiotic-resistance genes of several integrons. Gene 142:49-54[CrossRef][Medline]. |
| 14. | Lévesque, C., L. Piché, C. Larose, and P. H. Roy. 1995. PCR mapping of integrons reveals several novel combinations of resistance genes. Antimicrob. Agents Chemother. 39:185-191[Abstract]. |
| 15. |
Marchandin, H.,
H. Jean-Pierre,
C. De Champs,
D. Sirot,
H. Darbas,
P. F. Perigault, and C. Carrière.
2000.
Production of a TEM-24 plasmid-mediated extended-spectrum -lactamase by a clinical isolate of Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
44:213-216 |
| 16. |
Matagne, A.,
J. Lamotte-Brasseur, and J.-M. Frère.
1998.
Catalytic properties of class A -lactamases: efficiency and diversity.
Biochem. J.
330:581-598.
|
| 17. |
Maveyraud, L.,
L. Mourey,
L. P. Kotra,
J.-D. Pedelacq,
V. Guillet,
S. Mobashery, and J.-P. Samama.
1998.
Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A -lactamases from the antibiotic-resistant bacteria.
J. Am. Chem. Soc.
120:9748-9752[CrossRef].
|
| 18. |
Mourey, L.,
K. Miyashita,
P. Swaren,
A. Bulychev,
J.-P. Samama, and S. Mobashery.
1998.
Inhibition of the NMC-A -lactamase by a penicillanic acid derivative, and the structural bases for the increase in substrate profile of this antibiotic resistance enzyme.
J. Am. Chem. Soc.
120:9343-9383.
|
| 19. |
Naas, T., and P. Nordmann.
1994.
Analysis of a carbapenem-hydrolyzing class A -lactamase from Enterobacter cloacae and of its Lys-R type regulatory protein.
Proc. Natl. Acad. Sci. USA
91:7693-7696 |
| 20. |
Naas, T.,
L. Poirel,
A. Karim, and P. Nordmann.
1999.
Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum -lactamase VEB-1 in Pseudomonas aeruginosa.
FEMS Microbiol. Lett.
176:411-419[Medline].
|
| 21. |
Naas, T.,
L. Vandel,
W. Sougakoff,
D. Livermore, and P. Nordmann.
1994.
Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A, -lactamase, Sme-1 from Serratia marcescens S6.
Antimicrob. Agents Chemother.
38:1262-1270 |
| 22. | National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 23. |
Nordmann, P., and M. Guibert.
1998.
Extended-spectrum -lactamases in Pseudomonas aeruginosa.
J. Antimicrob. Chemother.
42:128-131 |
| 24. |
Nordmann, P.,
S. Mariotte,
T. Naas,
R. Labia, and M.-H. Nicolas.
1993.
Biochemical properties of a carbapenem-hydrolyzing -lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli.
Antimicrob. Agents Chemother.
37:939-946 |
| 25. |
Nordmann, P., and T. Naas.
1994.
Sequence analysis of PER-1 extended spectrum -lactamase from Pseudomonas aeruginosa and comparison with class A -lactamases.
Antimicrob. Agents Chemother.
38:104-114 |
| 26. |
Paulsen, I. T.,
T. G. Littlejohn,
P. Radström,
L. Sundström,
O. Sköld,
G. Swedberg, and R. A. Skurray.
1993.
The 3' conserved segment of integrons contains a gene associated with multidrug resistance to antiseptics and disinfectants.
Antimicrob. Agents Chemother.
37:761-768 |
| 27. |
Philippon, L. N.,
T. Naas,
A.-T. Bouthors,
V. Barakett, and P. Nordmann.
1997.
OXA-18, a class D clavulanic acid-inhibited extended-spectrum -lactamase from Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
41:2188-2195[Abstract].
|
| 28. |
Poirel, L.,
I. Le Thomas,
T. Naas,
A. Karim, and P. Nordmann.
2000.
Biochemical sequence analyses of GES-1, a novel class A extended-spectrum -lactamase, and the class 1 integron In52 from Klebsiella pneumoniae.
Antimicrob. Agents Chemother.
44:622-632 |
| 29. |
Poirel, L.,
T. Naas,
M. Guibert,
E. B. Chaibi,
R. Labia, and P. Nordmann.
1999.
Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum -lactamase encoded by an Escherichia coli integron gene.
Antimicrob. Agents Chemother.
43:573-581 |
| 30. |
Poirel, L.,
T. Naas,
D. Nicolas,
L. Collet,
S. Bellais,
J.-D. Cavallo, and P. Nordmann.
2000.
Characterization of VIM-2, a carbapenem-hydrolyzing metallo- -lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.
Antimicrob. Agents Chemother.
44:891-897 |
| 31. |
Poirel, L.,
E. Ronco,
T. Naas, and P. Nordmann.
1999.
Extended-spectrum -lactamase TEM-4 in Pseudomonas aeruginosa.
Clin. Microbiol. Infect.
5:651-652[Medline].
|
| 32. |
Poirel, L.,
V. O. Rotimi,
E. M. Mokaddas,
A. Karim, and P. Nordmann.
2001.
VEB-1-like extended-spectrum -lactamases in Pseudomonas aeruginosa, Kuwait.
Emerg. Infect. Dis.
7:468-470[Medline].
|
| 33. |
Queenan, A. M.,
C. Torres-Viera,
H. S. Gold,
Y. Carmeli,
G. M. Eliopoulos,
R. C. Moellering, Jr.,
J. P. Quinn,
J. Hindler,
A. A. Medeiros, and K. Bush.
2000.
SME-type carbapenem-hydrolyzing class A -lactamases from geographically diverse Serratia marcescens strains.
Antimicrob. Agents Chemother.
44:3035-3039 |
| 34. |
Raquet, X.,
J. Lamotte-Brasseur,
F. Bouillenne, and J.-M. Frère.
1997.
A disulfide bridge near the active site of carbapenem-hydrolyzing class A -lactamases might explain their unusual substrate profile.
Proteins
27:47-58[CrossRef][Medline].
|
| 35. |
Rasmussen, B. A.,
K. Bush,
D. Keeney,
Y. Yang,
R. Hare,
C. O'Gara, and A. A. Medeiros.
1996.
Characterization of IMI-1 -lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae.
Antimicrob. Agents Chemother.
40:2080-2086[Abstract].
|
| 36. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 37. |
Taibi, P., and S. Mobashery.
1995.
Mechanism of turnover of imipenem by the TEM -lactamase revisited.
J. Am. Chem. Soc.
117:7600-7605[CrossRef].
|
| 38. |
Tribuddharat, C., and M. Fennewald.
1999.
Integron-mediated rifampin resistance in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
43:960-962 |
| 39. |
Vahaboglu, H.,
R. ÖOztürk,
G. Aygun,
F. Coskunkan,
A. Yaman,
A. Kaygusuz,
H. Leblebicioglu,
I. Balik,
K. Aydin, and M. Otkun.
1997.
Widespread detection of PER-1-type extended-spectrum -lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study.
Antimicrob. Agents Chemother.
41:2265-2269[Abstract].
|
| 40. |
Yigit, H.,
A. M. Queenan,
G. J. Anderson,
A. Domenech-Sanchez,
J. W. Biddle,
C. D. Steward,
S. Alberti,
K. Bush, and F. C. Tenover.
2001.
Novel carbapenem-hydrolyzing -lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.
Antimicrob. Agents Chemother.
45:1151-1161 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»